Advertisement
Loading...

ImmunoGen, Inc.

IMU.DEXETRA
Healthcare
Biotechnology
5.17
0.00(0.00%)
German Market opens in 15h 29m

ImmunoGen, Inc. (IMU.DE) Stock Competitors & Peer Comparison

See (IMU.DE) competitors and their performances in Stock Market.

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
IMU.DE€5.17+0.00%1.1B-9.22-€0.56N/A
NOV.DE€40.01+2.29%173.6B10.65€3.67+4.02%
VX1.DE€365.00+0.70%92.5B25.26€14.40N/A
DUL.DE€249.05-1.15%33.6B127.89€1.97N/A
22UA.F€80.85+0.94%20.1B-15.64-€5.07N/A
0QF.F€48.83+18.16%18.5B-6.69-€6.95N/A
BM8.DE€61.96-1.71%11.8B88.51€0.70N/A
EX9.DE€32.28+1.22%9.2B35.47€0.91N/A
BBZA.DE€49.65+1.64%2.7B-5.66-€8.60+5.07%
MOR.DE€67.25-0.66%2.5B-12.16-€5.53N/A
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

IMU.DE vs NOV.DE Comparison May 2026

IMU.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IMU.DE stands at 1.1B. In comparison, NOV.DE has a market cap of 173.6B. Regarding current trading prices, IMU.DE is priced at €5.17, while NOV.DE trades at €40.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IMU.DE currently has a P/E ratio of -9.22, whereas NOV.DE's P/E ratio is 10.65. In terms of profitability, IMU.DE's ROE is -0.93%, compared to NOV.DE's ROE of +0.66%. Regarding short-term risk, IMU.DE is less volatile compared to NOV.DE. This indicates potentially lower risk in terms of short-term price fluctuations for IMU.DE.Check NOV.DE's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions